Cytomx Therapeutics Inc. has received clearances from the FDA for IND applications for two conditionally activated Probody therapeutics.

IMU Biosciences Ltd. has raised £11.5 million (US$14.7 million) in a series A round to further develop and commercialize profiling technology that can identify from a blood sample which of more than 2,000 cell types are present in an individual’s immune system.

One-third of patients with acute myeloid leukemia (AML) present mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. Several first- and next-generation FLT3 inhibitors are currently being used in AML management, but there is a need for new options able to achieve complete and sustained FLT3 signaling suppression.

Many patients with cancer in advanced stages develop cachexia, a metabolic disorder characterized by systemic weight loss and muscle and adipose tissue wasting.

Amphista Therapeutics Ltd. has announced new datasets with its next-generation bifunctional protein degraders demonstrating in vivo efficacy and the ability to target and degrade proteins in the central nervous system (CNS).